Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan · Delayed Price · Currency is JPY

942.00

-18.00 (-1.88%)

Aug 6, 2026, 1:22 PM JST

TYO:4570 Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1,004	1,004	969	816	794	647
Revenue Growth	3.61%	3.61%	18.75%	2.77%	22.72%	7.47%
Gross Profit	706	706	634	516	526	376
Operating Income	281	281	209	110	52	-122
Net Income	329	329	249	186	-289	-258
Earnings Per Share	35.33	35.33	26.74	19.97	-31.03	-27.70
EPS Growth	32.13%	32.13%	33.87%	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Antibody Related Business	1,002	1,002	964.37	812.85	790.6	637.47
Cosmetics Related	2.68	2.68	5.16	3.85	4.02	13.35
Total	1,005	1,005	969.53	816.7	794.62	647.58

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	989	989	825	734	614	508
Total Debt	176	176	204	235	234	233
Net Cash (Debt)	813	813	621	499	380	275
Net Cash Growth	30.92%	30.92%	24.45%	31.32%	38.18%	-46.50%
Net Cash Per Share	87.29	87.29	66.68	53.58	40.80	29.53

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	301	301	183	133	26	-93
Capital Expenditures	-33	-33	-59	-16	-	-
Free Cash Flow	268	268	124	117	26	-93
Free Cash Flow Growth	116.13%	116.13%	5.98%	350.00%	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	70.32%	70.32%	65.43%	63.23%	66.25%	58.11%
Operating Margin	27.99%	27.99%	21.57%	13.48%	6.55%	-18.86%
Pretax Margin	29.98%	29.98%	21.67%	15.20%	-35.26%	-38.64%
Profit Margin	32.77%	32.77%	25.70%	22.79%	-36.40%	-39.88%
FCF Margin	26.69%	26.69%	12.80%	14.34%	3.28%	-14.37%

Dividends

Fiscal Year	Current	FY 2026
Period Ending	Aug '26 Aug 6, 2026	Mar '26 Mar 31, 2026
Dividend Per Share	7.500	6.000
Dividend Per Share Growth	0%	-
Dividend Yield	0.78%	0.45%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug '26 Aug 6, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	27.18	37.99	17.95	26.49	-	-
P/FCF Ratio	33.36	46.64	36.05	42.11	145.79	-
PS Ratio	8.91	12.45	4.61	6.04	4.77	4.71